Indications for: LOPRESSOR HCT
Titrate individual components. Give in 1–2 divided doses. Max 50mg/day HCTZ.
LOPRESSOR HCT Contraindications:
Cardiogenic shock. Decompensated heart failure. Sinus bradycardia. Sick-sinus syndrome. Greater than 1st-degree block, unless paced. Anuria. Sulfonamide allergy.
LOPRESSOR HCT Warnings/Precautions:
Ischemic heart disease. Worsening cardiac failure (reduce or interrupt dose if necessary). Bronchospastic disease. Conduction disorders (including Wolff-Parkinson-White). Monitor HR; reduce dose or discontinue if severe bradycardia occurs. Major surgery. Renal or hepatic impairment. Volume depletion. Diabetes and hypoglycemia. Monitor serum electrolytes periodically. Peripheral vascular disease. Pheochromocytoma. Thyrotoxicosis (hyperthyroidism). History of severe anaphylactic reactions. Acute myopia. Secondary angle-closure glaucoma. SLE. Gout. Avoid abrupt cessation (gradually reduce dose over 1–2 weeks and monitor). Elderly. Pregnancy. Nursing mothers: monitor infants.
LOPRESSOR HCT Classification:
Cardioselective beta-blocker + diuretic.
LOPRESSOR HCT Interactions:
Additive effects with catecholamine-depleting drugs (eg, reserpine, monoamine oxidase). Potentiated by strong CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine, propafenone); monitor closely if concomitant use is unavoidable. Risk of bradycardia with digitalis, clonidine, diltiazem, verapamil. Potentiated by alcohol, CNS depressants, other antihypertensives. Adjust antidiabetic medication. Decreased absorption with cholestyramine and colestipol resins. Beta-blockers may mask signs of hypoglycemia. May increase lithium toxicity. Antagonized by NSAIDs. May antagonize epinephrine.
Fatigue, bronchospasm, dizziness, drowsiness, headache, fluid or electrolyte imbalance, bradycardia, depression, dyspnea, GI upset, blurred vision, tinnitus, earache, impotence, myalgia, cold extremities, CHF, heart block.
Generic Drug Availability: